Evidence map›Paper›PMID 37833604›Full record

ArticleDoklady. Biochemistry and biophysics2023

Are the Goals of Therapy Achievable in Patients with Rheumatoid Arthritis Receiving Upadacitinib in Real Clinical Practice?

V N Amirdzhanova, A E Karateev, E Yu Pogozheva, E S Filatova, R R Samigullina, V I Mazurov, O N Anoshenkova, N A Lapkina, A A Baranov, T Yu Grineva and 2 more

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

V N AmirdzhanovaNasonova Research Institute of Rheumatology, Moscow, Russia. amirver@yandex.ru.
A E KarateevNasonova Research Institute of Rheumatology, Moscow, Russia.
E Yu PogozhevaNasonova Research Institute of Rheumatology, Moscow, Russia.
E S FilatovaNasonova Research Institute of Rheumatology, Moscow, Russia.
R R SamigullinaMechnikov Northwestern State Medical University, Ministry of Health of the Russian Federation, St. Petersburg, Russia.
V I MazurovMechnikov Northwestern State Medical University, Ministry of Health of the Russian Federation, St. Petersburg, Russia.
O N AnoshenkovaMedical Center "Maximum Health", Tomsk, Russia.
N A LapkinaYaroslavl State Medical University, Ministry of Health of the Russian Federation, Yaroslavl, Russia.
A A BaranovYaroslavl State Medical University, Ministry of Health of the Russian Federation, Yaroslavl, Russia.
T Yu GrinevaVologda Regional Clinical Hospital No. 1, Vologda, Russia.
A M LilaNasonova Research Institute of Rheumatology, Moscow, Russia.
E L NasonovNasonova Research Institute of Rheumatology, Moscow, Russia.
Association of Rheumatologists of Russia · RUMinistry of Health of the Russian Federation · RUYaroslavl State Medical Academy · RURussian Medical Academy of Continuous Professional Education · RUSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study was to evaluate the effectiveness of UPA in RA patients in real clinical practice after 3 and 6 months of therapy. The study included 63 RA patients with high activity of the disease. Activity was assessed according to the DAS28(ESR), DAS28(CRP), SDAI, CDAI; functional ability to HAQ; quality of life to the EQ-5D; disease activity according to the patient's RAPID-3 index; the level of depression and anxiety to the HADS scale. The effectiveness of therapy was evaluated after 3 (n = 45) and 6 (n = 31) months of UPA therapy. Remission or low activity of the disease by 3 months of therapy was achieved by most patients: remission of 69.8% of patients, low activity of the disease-16.3% of patients. Moderate or high activity persisted in 13.9% of patients. By the 6th month of UPA therapy, the number of remissions reached 90%, low activity 3.3%, moderate activity persisted in 6.7% of patients, high activity of the disease was not in any patient. 20% improvement in function was achieved in 71.8% of patients by the 3rd month of therapy and in 77.8% by the 6th month of treatment; the difference in average HAQ values by the 3rd month of therapy was 0.38 points, by the 6th month-0.58 points. After 3 months of follow-up, 31.1% of patients continued taking GC, by 6 months-24.2%. The dose of GC was reduced from an average of 7.23 to 5.6 mg/s. The percentage of patients requiring NSAIDs decreased from 95.2 to 35.6% and 33.3%, respectively. DMARDs continued to be received by 75.6% of patients by 3 months and 69.7% by 6 months of follow-up. Achieving remission or low activity of the disease in patients with RA receiving UPA in real clinical practice is possible in most patients. A rapid decrease in inflammatory activity is accompanied by a significant improvement in the functional state and quality of life of patients. UPA therapy reduces the need for the use of NSAIDs and reduces the dose of GC in a third of patients.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidAnti-Inflammatory Agents, Non-SteroidalGoalsHeterocyclic Compounds, 3-RingHumansQuality of LifeRemission InductionSeverity of Illness IndexTreatment OutcomeAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsHeterocyclic Compounds, 3-Ringupadacitinibremissionrheumatoid arthritisupadacitinib

Identifiers

PMID37833604
PMCPMC10739522
OpenAlexW4387606956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.